pd-1 blocking antibody + chidamide + lenalidomide + gemcitabine

This is a combination regimen consisting of four agents: - A PD-1 blocking antibody (immune checkpoint inhibitor targeting programmed cell death protein 1) - Chidamide (a selective histone deacetylase inhibitor) - Lenalidomide (an immunomodulatory and antiangiogenic small molecule) - Gemcitabine (a nucleoside analog antimetabolite chemotherapeutic) The combination is under investigation for the treatment of relapsed or refractory peripheral T-cell lymphoma and other hematologic malignancies. The rationale for this regimen is to combine immune checkpoint blockade with epigenetic modulation, immunomodulation, and cytotoxic chemotherapy to enhance antitumor efficacy. Each component has demonstrated activity in lymphomas either as monotherapy or in various combinations; preclinical and early clinical data suggest potential synergistic effects when used together[3][7].

Other names

PD-1 antibody, chidamide, lenalidomide and gemcitabinePD-1 antibody + chidamide + lenalidomide + gemcitabine combination